Navigation Links
Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Date:8/11/2011

uch factors as the receipt and timing of FDA and other regulatory reviews and approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, we may experience unexpected regulatory actions, delays or requests, our future clinical trials may not be successful, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2010 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:
Brian Ritchie - FD
212-850-5683
brian.ritchie@fd.com

Media Contact:
Irma Gomez-Dib - FD
212-850-5761
irma.gomez-dib@fd.com


'/>"/>
SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Andrea Drucker Joins Insmed as General Counsel
2. Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
3. Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
4. Insmed to Host Second Quarter 2009 Conference Call
5. Insmed Announces Addition to the Russell 3000(R) Index
6. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
7. Insmed CEO Resigns Due to Health Concerns
8. Insmed Announces First Quarter 2009 Financial Results
9. Insmed Regains NASDAQ Compliance
10. Insmed to Host First Quarter 2009 Conference Call
11. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 PMG Research, Inc. ... Research is a network of sites that provide clinical research ... 2 million patient lives through its partnerships with large physician ... 11 hub site locations in the Southeastern United States and ... of the board will be held by: Dr. ...
(Date:11/26/2014)... Continuing its award-winning streak, Nerium International, the ... Awards for outstanding creative achievement by its marketing and ... the organization’s top honor, in the Branding category for ... April of this year. The event showcased top speakers ... was awarded a Gold MarCom Award in the Special ...
(Date:11/26/2014)... 26, 2014 SoundConnect , an ... proud to announce that Darren Suders has joined the ... Darren will drive the partner program through ... , Darren brings more than 10-years of ... roles in channel operations, from policy development, to partner ...
(Date:11/26/2014)... -- Bio-Techne Corporation (NASDAQ: TECH ) announced ... to serve in a newly created position of Senior ... will be responsible for managing the operations of Bio-Techne,s ... acquired in July 2014 and the recently acquired CyVek ... -based ProteinSimple develops and commercializes proprietary systems and consumables ...
Breaking Biology Technology:PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2SoundConnect Appoints Director of Channel Development & Sales 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 2Bio?Techne Announces Appointment Of Robert Gavin As Leader Of New Protein Platforms Division 3
... be participating in the Barclays Capital 2010 Global Healthcare Conference in Miami, Fla. , on March 23, 2010 , at 8:30 a.m. Eastern Time .   , ... , ... ... ...
... for life science researchers, has selected Biodiagnostics as its new distributor of IPA® in Greece , Turkey ... systems at the core of life science research. , ... ... ...
... patient cases using magnetic resonance-guided heat (laser interstitial ... cancer recurrence after surgical removal of the prostate ... of Interventional Radiology,s 35th Annual Scientific Meeting in ... salvage radiation treatment and are often presented with ...
Cached Biology Technology:Zimmer Holdings to Present at Barclays Capital 2010 Global Healthcare Conference 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 2Ingenuity Systems Announces New Distributor for Greece, Turkey and the Balkans 3The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 2The hot -- and cold -- interventional radiology treatments for recurrent prostate cancer 3
(Date:11/4/2014)... marketing directed at children on the interior and ... the majority of black, middle-income and rural communities ... Authored by Arizona State University researcher Punam Ohri-Vachaspati ... to examine the use of child-directed marketing on ... and its relationship to demographics. It adds to ...
(Date:11/4/2014)... – (Nov. 4, 2014) – A majority of Madagascar,s ... that could have serious consequences for the rainforests they ... shows the positive impacts lemurs can have on rainforest ... their disappearance could have on the region,s rich biodiversity. ... have fruits eaten by lemurs. Lemurs in turn ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and Markets ... "Cell Therapy - Technologies, Markets and Companies" to their ... therapy technologies and methods, which have already started to play ... cell transplantation is replacing the old fashioned bone marrow transplants. ... therapy is bound to become a part of medical practice. ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3
... to study addicted,smokers, a new drug that attaches ... implicated in nicotine addiction ,may help studies ... and schizophrenia.,Developed by UC Irvine Transdisciplinary Tobacco Use ... selective binding agent,that identifies specific areas of the ...
... may be precipitated by a "traffic jam" within neurons ... and structures in the cells, according to new studies ... models of Alzheimer's disease and in human brain samples ... breakdown in neurons that appears to prevent the normal ...
... Scientists at Joslin Diabetes Center have discovered one reason why ... developing type 2 diabetes later in life. In studies of ... pancreas's ability to later secrete enough insulin in response to ... don't have delivery of enough nutrients from the mother to ...
Cached Biology News:Drug That 'Tags' Decision-making Areas Of The Brain May Aid 2Neuronal 'traffic jam' marks early Alzheimer's disease 2Neuronal 'traffic jam' marks early Alzheimer's disease 3Neuronal 'traffic jam' marks early Alzheimer's disease 4Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 2Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 3Poor prenatal nutrition permanently damages function of insulin-producing cells in the pancreas 4
The new Silencer siRNA Starter Kit is perfect for researchers new to RNAi. It provides all of the reagents, protocols, and instructions necessary to get underway with siRNA transfection and ensure su...
... protein Vtg in plasma from juvenile or male ... endocrine disrupting chemicals (EDCs) with estrogenic effects in ... screening test for the estrogenic effects of EDCs ... is a double-antibody immunometric (sandwich) EIA for analyzing ...
... is a 17 amino acid synthetic peptide whose sequence is from ... to carboxy terminus): C - N(217) - Q - P ... A - T - P - N - Y - T ... be used for neutralization and control experiments with the polyclonal antibody ...
... for which no antibody exists? Having difficulty generating ... a variety of pharmaceutical, biotech and academic researchers ... technology and expertise in antibody generation to work ... RabMAb development technology , High affinity and high ...
Biology Products: